OVERVIEW

Incorporating New Guidelines to Lower LDL-C and Reduce ASCVD Risk is organized by Rockpointe Corporation.

Release date: October 31, 2019
Expiration date: October 31, 2020

Accreditation:
Physician Credit Designation?
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
In late 2018, two new blood cholesterol guidelines were published. To increase the use of risk-assessment tools to identify patients at increased risk for ASCVD, the ACC released a guide to decision-making for primary prevention of ASCVD. The second, jointly published by a large number of societies including the AHA and ACC, updated the recommendations for managing blood cholesterol. This document provided strategies for primary prevention and secondary prevention of ASCVD and approaches for modifying therapy for patients not achieving LDL-C goals.

To achieve the AHA’s 2020 impact goals of improving the cardiovascular health of all Americans by 20%, while reducing deaths attributable to cardiovascular disease and stroke by 20%, clinicians need to incorporate these new guidelines into clinical practice. This activity will provide a review of these recent evidence-based recommendations, as well as information about non-statin agents recommended for use when patients are not at LDL-C goal.

Educational Objectives:
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
• Evaluate the need for blood cholesterol management in the primary prevention of ASCVD by using tools recommended in the 2018 AHA/ACC guidelines
• Develop individualized primary prevention strategies for patients with and without severe hypercholesterolemia using the 2018 cholesterol guidelines
• Implement management plans for the secondary prevention of ASCVD using recommendations from the 2018 blood cholesterol guidelines
• Use adjunctive non-statin therapy when secondary prevention with statins alone does not achieve 2018 blood cholesterol guideline goals